N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=27 CampETEC Hyperimmune Bovine Colostrum (HBC)
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events
Phase 1 N=60 Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge
Healthy Volunteer
Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants
N/A N=23 Pre-Study of Wild Type Enterotoxigenic E. Coli (ETEC) Strain for Verification of a Planned Challenge Dose
ETEC Diarrhea
Primary: Number of Participants With Moderate and Severe Diarrhea — 17 participants moderate or severe diarrea
N/A N=700 Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients
Urinary Tract Infection · Infection Due to ESBL Bacteria · Environmental Contamination of ESBL
Primary: Treatment Failure — 23; 101 Treatment success
Phase 1 N=36 Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli
Urinary Tract Infections
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by DAIDS v2.1 — 0; 0 Participants
N/A N=60 Improvements Through the Use of a Rapid Multiplex PCR Enteric Pathogen Detection Kit in Children With Hematochezia
Diarrhea Bloody
Primary: Blood Test Performance — 18; 17 Participants
Phase 1 N=10 Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study
Urinary Tract Infection
Primary: Rate of UTI While Colonized With E. Coli 83972. — 8.5 UTIs per 1000 patient-days
Phase 2 N=94 Inulin for Infections in the Intensive Care Unit
Antibiotic Resistant Infection · Nosocomial Infection · Pathogen Transmission
Primary: Within-individual Change in SCFA Producer Level — -0.0; -1.8; 1.1 percentage of SCFA producers
Phase 3 N=503 Study to Evaluate Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery
Infections
Primary: Number of Participants In Intent to Treat (ITT) Analysis Set With Superficial and Deep Incisional Surgical Site Infections (SSI) Involving Principal Incision Within 30…
Phase 3 N=271 Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)
Urinary Tract Infection
Primary: Microbiological Response Assessment Profile — 58; 63 Participants
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Phase 4 N=200 Ciprofloxacin for Prevention of BK Infection
BK Virus Infection
Primary: Number of Patients Developing BK Infection at 6 Months Post-transplant — 25; 5 Participants
Phase 1 N=50 Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)
Diarrhea
Primary: Number of Participants With Solicited Adverse Events — 2; 5; 9; 9 Participants
Phase 4 N=57 Effects of Antibiotic Prophylaxis on Recurrent UTI in Children
Urinary Tract Infection · Recurrent Urinary Tract Infection
Primary: Changes to the Urinary Microbiota — 3; 2; 1 participants
N/A N=139 Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection in Adult Women
Recurrent Urinary Tract Infection in Adult Women
Primary: To Evaluate the Effect of Oral Supplementation With Lactobacillus Reuteri on the Frequency of Confirmed UTI in Adult Women With Recurrent UTI. — 1.2; 1.3 Number of…
N/A N=28 Human Challenge Model Refinement With Enterotoxigenic Escherichia Coli Strain B7A
Healthy Volunteer
Primary: Number of Participants With Safety- Solicited Symptoms Related to Challenge Administration — 0; 0; 3; 2 Participants
N/A N=33 Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care
Antibiotic Resistant Infection · Infection
Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate
Phase 4 N=434 Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System
Intraventricular Hemorrhage · Subarachnoid Hemorrhage
Primary: Number of Infections — 4; 5; 4; 5 Infections
Phase 3 N=541 Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections
Complicated Intra-abdominal Infections
Primary: Clinical Response of Eravacycline and Ertapenem Treatment Arms at the Test-of-cure (TOC) Visit in the Microbiological Intent-to-treat (Micro-ITT) Population — 191; 198…
N/A N=3,153 COMBACTE-CDI Understanding the Burden of C. Difficile Infection
Clostridium Difficile Infection
Primary: The Number of Cases of CDI — 103; 0 Participants
Phase 3 N=500 Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections
Complicated Intra-abdominal Infections · Complicated Appendicitis
Primary: Number of Participants With a Favorable Clinical Response at the Test-of-Cure (TOC) Visit in the Microbiological Intent-to-treat (Micro-ITT) Population — 177; 187; 7; 7…
Phase 1 N=13 Colonizing Neurogenic Bladders With Benign Flora
Spinal Cord Injury · Urinary Tract Infection
Primary: Bladder Colonization — 62 percentage of participants
N/A N=272 Seven vs. 14 Days Treatment for Male Urinary Tract Infection
Urinary Tract Infections
Primary: Resolution of UTI Symptoms 14 Days After Completing Active Antimicrobial Therapy — 111; 122 Participants
Phase 2 N=370 Gentamicin Intravesical Efficacy for Infection of Urinary Tract
Postoperative Urinary Tract Infection · Pelvic Organ Prolapse · Stress Urinary Incontinence
Primary: Post-operative Urinary Tract Infection — 19; 20 Participants
N/A N=702 Prospective, Randomized, Parallel-arm Clinical Trial of CleanCision or Alexis O in Elective Colorectal Surgery
Colorectal Surgery
Primary: Surgical Site Infection (SSI) Rate — 16; 14; 6; 1 Participants
Phase 4 N=60 Management of Sub-Clinical Bacteriuria in Pregnancy
Cystitis · Cystitis;Puerperium · Pyelonephritis
Primary: Number of Participants Who Have Cystitis — 4; 4 Participants
Phase 2 N=452 A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
Urinary Tract Infections
Primary: Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure — 72.6; 54.6 percentage of participants
Phase 2 N=90 Continuous Antibiotic Prophylaxis in Colorectal Surgery
Surgical Site Infection
Primary: Number of Patients With a Surgical Site Infection — 10; 13 Participants
Phase 4 N=23 Concentration of Ertapenem in Colorectal Tissue
Diverticulosis, Colonic · Rectal Neoplasms · Colonic Neoplasms
Primary: Concentration of Ertapenem in Colorectal Tissue in mg/kg 3 to 6 Hours After a Single Dose of 1 Gram Ertapenem I.V..